StockEdge.com
  • Products
    • StockEdge Premium
    • StockEdge Pro
    • StockEdge Club
    • Compare Plans
StockEdge Blog
  • Trending Stocks
  • Insights
    • All
    • Business Houses
    • Markets themes
    • Stock Insights
    Zomato Shares

    Zomato Shares/Stock Analysis: Profile, Financials & Growth

    Aster DM Healthcare’s Spinoff of Gulf Hospitals – A Special Situation You Can’t Afford to Miss!

    Aster DM Healthcare’s Spinoff of Gulf Hospitals – A Special Situation You Can’t Afford to Miss!

    An image charging the electric vehicle from e-station and Text written on the right side

    India’s Top Electric Vehicle(EV) Stocks

    Top 5 Textile stocks

    Top 5 Textile Stocks in India: From Cotton to Cash

    multi-bagger stocks for 2025

    5 Multibagger Stocks to keep an eagle-eye for 2025

    Jindal Saw – Strong Earnings Momentum Ahead

    Jindal Saw – Strong Earnings Momentum Ahead

    Kirloskar Group- A Legacy of 134 Years

    Kirloskar Group- A Legacy of 134 Years

    renewable energy stocks in india

    Top Renewable Energy Stocks in India

    blue chip stocks

    Top 5 Blue Chip Stocks to Buy and Invest in 2023

  • Technical Analysis
    Chart Patterns – Holy grail of Stock Market Analysis

    Chart Patterns – Holy grail of Stock Market Analysis

    StockEdge Version Update : 9.0

    StockEdge Version Update : 9.0

    Beat the street with Sector Rotation Strategy

    Beat the street with Sector Rotation Strategy

    StockEdge Version Update 8.2

    StockEdge Version Update 8.2

    Derivative Analytics

    An Insightful Research Tool For Derivative Analytics

    Introducing Put-Call Ratio a Derivative Indicator in the Market

    Introducing Put-Call Ratio a Derivative Indicator in the Market

    A Powerful Technical Indicator Beta & Beta Scans

    A Powerful Technical Indicator Beta & Beta Scans

    Technical Analysis using Edge Charts

    Technical Analysis using Edge Charts

    adaptive relative strength and static relative strength scans

    What is Adaptive Relative Strength & Static Relative Strength Scans?

  • Fundamental Analysis
    • All
    • Cash Flow Ratios
    • Efficiency ratios
    • Growth Ratios
    • Liquidity Ratios
    • Return Ratios
    • Solvency ratios
    • Valuation Ratios
    high dividend paying stocks

    Identifying High Dividend Paying Stocks

    Understanding the Importance of creating Fundamental Scans

    Understanding the Importance of creating Fundamental Scans

    Using My Combination Scan to Identify best in an Industry

    Using My Combination Scan to Identify best in an Industry

    Cost Income ratio

    Cost to Income Ratio(%)

    Cost of Liability

    Cost of Liabilities (%)

    Operating Cost to Assets Ratio (%)

    Operating Cost to Assets Ratio (%)

  • StockEdge Tutorials
    Simplify stock market analysis with Edge Reports | StockEdge

    Simplify stock market analysis with Edge Reports | StockEdge

    StockEdge Club: An Exclusive Investors Hub & Analytics platform

    StockEdge Club: An Exclusive Investors Hub & Analytics platform

    FII/DII Data: Leading Indicators of Stock Market

    FII/DII Data: Leading Indicators of Stock Market

    Chart Patterns – Holy grail of Stock Market Analysis

    Chart Patterns – Holy grail of Stock Market Analysis

    StockEdge Version Update : 9.0

    StockEdge Version Update : 9.0

    Powerful Investment Themes for Retail Investors

    Powerful Investment Themes for Retail Investors

    Beat the street with Sector Rotation Strategy

    Beat the street with Sector Rotation Strategy

    StockEdge Version Update 8.3

    StockEdge Version Update 8.3

    StockEdge Version Update 8.2

    StockEdge Version Update 8.2

  • Mutual Fund
    Top 5 Mutual Funds for 2022 where you can start your SIP

    Top 5 Mutual Funds for 2022 where you can start your SIP

    What are Value Funds and its Advantages?

    What are Value Funds and its Advantages?

    thematic funds

    Thematic Funds : Everything you need to know

    Understanding Sector Funds and their Benefits to our Portfolio

    Understanding Sector Funds and their Benefits to our Portfolio

    Are Dividend Yield Funds a good option to invest in?

    Are Dividend Yield Funds a good option to invest in?

    What are Contra Funds and their advantages?

    What are Contra Funds and their advantages?

    Trending Tags

    No Result
    View All Result
    • Trending Stocks
    • Insights
      • All
      • Business Houses
      • Markets themes
      • Stock Insights
      Zomato Shares

      Zomato Shares/Stock Analysis: Profile, Financials & Growth

      Aster DM Healthcare’s Spinoff of Gulf Hospitals – A Special Situation You Can’t Afford to Miss!

      Aster DM Healthcare’s Spinoff of Gulf Hospitals – A Special Situation You Can’t Afford to Miss!

      An image charging the electric vehicle from e-station and Text written on the right side

      India’s Top Electric Vehicle(EV) Stocks

      Top 5 Textile stocks

      Top 5 Textile Stocks in India: From Cotton to Cash

      multi-bagger stocks for 2025

      5 Multibagger Stocks to keep an eagle-eye for 2025

      Jindal Saw – Strong Earnings Momentum Ahead

      Jindal Saw – Strong Earnings Momentum Ahead

      Kirloskar Group- A Legacy of 134 Years

      Kirloskar Group- A Legacy of 134 Years

      renewable energy stocks in india

      Top Renewable Energy Stocks in India

      blue chip stocks

      Top 5 Blue Chip Stocks to Buy and Invest in 2023

    • Technical Analysis
      Chart Patterns – Holy grail of Stock Market Analysis

      Chart Patterns – Holy grail of Stock Market Analysis

      StockEdge Version Update : 9.0

      StockEdge Version Update : 9.0

      Beat the street with Sector Rotation Strategy

      Beat the street with Sector Rotation Strategy

      StockEdge Version Update 8.2

      StockEdge Version Update 8.2

      Derivative Analytics

      An Insightful Research Tool For Derivative Analytics

      Introducing Put-Call Ratio a Derivative Indicator in the Market

      Introducing Put-Call Ratio a Derivative Indicator in the Market

      A Powerful Technical Indicator Beta & Beta Scans

      A Powerful Technical Indicator Beta & Beta Scans

      Technical Analysis using Edge Charts

      Technical Analysis using Edge Charts

      adaptive relative strength and static relative strength scans

      What is Adaptive Relative Strength & Static Relative Strength Scans?

    • Fundamental Analysis
      • All
      • Cash Flow Ratios
      • Efficiency ratios
      • Growth Ratios
      • Liquidity Ratios
      • Return Ratios
      • Solvency ratios
      • Valuation Ratios
      high dividend paying stocks

      Identifying High Dividend Paying Stocks

      Understanding the Importance of creating Fundamental Scans

      Understanding the Importance of creating Fundamental Scans

      Using My Combination Scan to Identify best in an Industry

      Using My Combination Scan to Identify best in an Industry

      Cost Income ratio

      Cost to Income Ratio(%)

      Cost of Liability

      Cost of Liabilities (%)

      Operating Cost to Assets Ratio (%)

      Operating Cost to Assets Ratio (%)

    • StockEdge Tutorials
      Simplify stock market analysis with Edge Reports | StockEdge

      Simplify stock market analysis with Edge Reports | StockEdge

      StockEdge Club: An Exclusive Investors Hub & Analytics platform

      StockEdge Club: An Exclusive Investors Hub & Analytics platform

      FII/DII Data: Leading Indicators of Stock Market

      FII/DII Data: Leading Indicators of Stock Market

      Chart Patterns – Holy grail of Stock Market Analysis

      Chart Patterns – Holy grail of Stock Market Analysis

      StockEdge Version Update : 9.0

      StockEdge Version Update : 9.0

      Powerful Investment Themes for Retail Investors

      Powerful Investment Themes for Retail Investors

      Beat the street with Sector Rotation Strategy

      Beat the street with Sector Rotation Strategy

      StockEdge Version Update 8.3

      StockEdge Version Update 8.3

      StockEdge Version Update 8.2

      StockEdge Version Update 8.2

    • Mutual Fund
      Top 5 Mutual Funds for 2022 where you can start your SIP

      Top 5 Mutual Funds for 2022 where you can start your SIP

      What are Value Funds and its Advantages?

      What are Value Funds and its Advantages?

      thematic funds

      Thematic Funds : Everything you need to know

      Understanding Sector Funds and their Benefits to our Portfolio

      Understanding Sector Funds and their Benefits to our Portfolio

      Are Dividend Yield Funds a good option to invest in?

      Are Dividend Yield Funds a good option to invest in?

      What are Contra Funds and their advantages?

      What are Contra Funds and their advantages?

      Trending Tags

      No Result
      View All Result
      StockEdge Blog
      Home Insights
      Biocon Limited – Transforming Healthcare. Transforming Lives.

      Biocon Limited – Transforming Healthcare. Transforming Lives.

      StockEdge by StockEdge
      March 3, 2021
      Reading Time: 5 mins read
      3.7k
      VIEWS
      Share on FacebookShare on TwitterShare On WhatsApp

      Table of Contents

      • The Story of Biocon Limited
        • Operational Highlights of Biocon Limited
        •  Future Outlook
        • Management Update
        • StockEdge Technical View
        • Bottom Line
      Biocon Limited

      The Story of Biocon Limited

      Established in 1978 with an initial seed capital of Rs 10,000 (US$ 140). Papain, an enzyme contained in papaya that is used to prevent beer from being hazy, was Biocon’s first product to go on the market. The company named Biocon Limited combined enzymes and supplied them to brewing, textiles, biofuels, animal feed, and other such industries around the world until 1983. As of today’s date, this is Biocon India share price.

      Kiran Mazumdar Shaw started Biocon India in the garage of her rented house in Bangalore.

      It became the first company in India to be able to produce enzymes and export them to the United States and Europe within a year of its founding, overcoming all the major challenges.

      She listed Biocon Limited on the stock market in 2004, after seeking advice from Narayana Murthy, to raise capital to be able to further expand Biocon’s research programs. It was India’s first biotechnology company to go public.

      Today, Biocon Limited is an integrated innovation-led biopharmaceutical company engaged in discovering, developing and producing biologics in chronic therapies. Key products include statins, immunosuppressants anti-diabetic drugs and specialty enzymes.

      Biocon has shaped its business into 4 key growth verticals with the aim to deliver sustainable long term value for patients, partners and healthcare across the globe-biologics, branded formulations, small molecules and research services.

      Biocon Limited
      Biocon Limited

      Building on core expertise in APIs, the company forward integrated into Generic Formulations for both developed and emerging markets, a few years ago. To stay abreast of the ever-growing competition in the generics business, Biocon has chosen to focus on niche therapeutic areas such as oncology, diabetes, autoimmune diseases and immunosuppressants over the next few years. Initially, the product selection was focused on leveraging supply reliability due to vertical integration in the chronic space of cardiovascular drugs and other chosen therapeutic areas.

      Biocon Limited

      Operational Highlights of Biocon Limited

      • The revenues grew during Q3FY21 to Rs.1851 cr as compared to Rs.1717 cr in Q3FY20. For the Generics segment, the revenue stood at ₹561 crore in Q3 and declined by 6.3% QoQ
      • The EBITDA declined to Rs.399 cr in Q3FY21 as compared to Rs.444 cr in Q3FY20. The company had an expense of Rs.183 crore on account of research & development and employee costs during the quarter.
      Biocon Limited
      • The PAT declined at Rs.187 in Q3FY21 as compared to Rs.233 cr in Q3FY20.
      • Abu-Dhabi based, Abu Dhabi Developmental Holding Company (ADQ) would invest ₹555 crore for a minority stake of 1.8% in Biocon Biologics. The valuation of Biocon Biologics post investment would be $4.17 billion.
      Biocon Limited

       Future Outlook

      • The management is sticking to the earlier revenue target of USD 1 bn by FY22 for biologics business on back of the current portfolio as well as the forthcoming launches.
      • It received approval from the National Pharmaceutical Regulatory Agency (NPRA), Malaysia, for Insulin Aspart and Bevacizumab.
      • The Research Services increased by 12.5% QoQ to ₹585 crore during the quarter. Syngene entered into collaboration with 3DC (Deerfield Discovery and Development) and expanded Hyderabad facility by adding capacity for additional scientists.

      Management Update

      • The manufacturing capacity of Insulin in India & Malaysia has the dimension to support demand of developing as well as emerging market segments. Its entry into countries like Japan and Russia was impacted by Covid-related challenges, such as delays in good manufacturing practice (GMP) audits.
      • Goldman Sachs did a capital injection of $150 million in exchange for optionally convertible debentures of Biocon Biologics.
      • Over 100 patients, out of a total of 300, were enrolled in Phase 4 clinical studies for Itolizumab in treating CRS (cytokine release syndrome) in moderate to severe ARDS (acute respiratory distress syndrome) due to Covid.

      Read our latest article on Vinati Organics Limited – Shaping a Reliable Future

      StockEdge Technical View

      Biocon Limited

      Biocon has a strong support at 365-370 zone and likely to stay positive in the medium term till the stock holds above support zone. Weakness to get extended only below 360 level. Probable resistance in the medium term comes at 450 level. Technical parameters look neutral as of now.

      Bottom Line

      Biocon Limited continues to diversify its portfolio with launches of Pegfilgrastim and Trastuzumab in the US market with its partner Mylan. Company has also received the approval for Trastuzumab and Insulin Glargine and is all set to enter in Latin America and commonwealth independent states, and commenced supply of Insulin Glargine in Malaysia. Company also filed for three APIs in the key regulated market. Timely launches and ramp up of biosimilar in the developed as well as EMs and Syngene’s performances remain key levers for the company.

      New products launches and smooth operation ahead amidst US FDA approval for most of the facility should support longer-term earning growth prospectus. Also, the Branded formulation and Biologics segment (impacted by COVID-19) should recover gradually. Biocon Limited has a strong pipeline of biosimilars to be launched over the next 3-5 years across various markets. Despite the competition, the biosimilar products have good potential to gain market share from its peers based on its track record. The CEO of the Biologic division has stepped down.

      Click here to know more about the Premium offering of StockEdge.

      You can check out the desktop version of StockEdge using this link.

      Tags: BioconLtdInvestingstock insights
      ShareTweetSend
      Subscribe On Telegram Subscribe On Telegram Subscribe On Telegram
      Previous Post

      What are Value Funds and its Advantages?

      Next Post

      Indiabulls Group – Enabling Growth, Enabling Trust

      StockEdge

      StockEdge

      StockEdge is a self-help Equity and Mutual Fund research tool. It empowers retail investors to identify investment opportunity with all the necessary data and analytics.

      Next Post
      Indiabulls Group – Enabling Growth, Enabling Trust

      Indiabulls Group – Enabling Growth, Enabling Trust

      adaptive relative strength and static relative strength scans

      What is Adaptive Relative Strength & Static Relative Strength Scans?

      StockEdge Version 6.0

      StockEdge Version 6.0

      Comments 4

      1. Ramesh Kousik says:
        2 years ago

        Very nice report …iam a begineer and got to know many thinghs from u guys .

        Thanks a lot

        • StockEdge says:
          2 years ago

          We are glad you liked the content. Keep following us on Twitter to read more such Blogs!

      2. Khalilur Choudhury says:
        2 years ago

        Hi Stock Edge team,

        You are doing a fabulous job. Your analysis and information sharing pattern are different, very easy to understand. Keep the good work continue. Lots of love.

        • StockEdge says:
          2 years ago

          We are glad you liked the content. Keep following us on Twitter to read more such Blogs!

      Contact Us
      • Timing (Mon-Sat): 10 am to 7 pm
      • Sales: +919830994463
      • Support: +919830994402
      • Club Support: +916289906895
      • Affiliate: +917003567131
      Recent Posts
      All About NIFTY50, Components of NIFTY50, and How to Invest in it
      Simplify stock market analysis with Edge Reports | StockEdge
      Important Links
      • StockEdge.com
      • StockEdge Premium
      • - Quarterly Membership
      • - Annual Membership
      • StockEdge Analyst
      • StockEdge Club
      • Compare Plans
      An Initiative Of

      © 2023 Kredent InfoEdge Pvt Ltd.

      Facebook-f Twitter Instagram Linkedin-in Youtube Pinterest-p

      Get StockEdge App

      No Result
      View All Result
      • Home
      • Article Categories
        • Fundamental Analysis
        • Technical Analysis
        • Market Themes
        • StockEdge Tutorials
        • StockEdge Version Updates
      • Products
        • StockEdge Premium
        • StockEdge Pro
        • StockEdge Club
        • Compare Plans
      • Visit StockEdge.com

      © 2023 Kredent InfoEdge Pvt Ltd.

      ELM School

      Premium or Pro or Club?

      The market is back in decent shape and the good time to invest in stock is finally here.
      Become a smart investor with a stunning deal! Use code DEAL30 to get any plan at 30% flat discount

      GET YOUR PLAN